Nalaganje...
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial. The hist...
Shranjeno v:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Public Library of Science (PLoS)
2014-01-01
|
| Serija: | PLoS ONE |
| Online dostop: | http://europepmc.org/articles/PMC3938434?pdf=render |
| Oznake: |
Označite
Brez oznak, prvi označite!
|